Literature DB >> 33595822

Presentation and outcome of chronic kidney disease in Italian and immigrant citizens: results from the Emilia-Romagna PIRP project.

Dino Gibertoni1, Leonardo Mammana2, Giulia Gherardi3, Erica Baschieri3, Francesco Minora3, Antonio Santoro4.   

Abstract

INTRODUCTION: In recent decades, high income countries (HIC) have been exposed to huge human migratory flows. Consistent with this influx, there has been a dramatic increase in the number of chronic kidney disease (CKD) patients in the immigrant population. In Italy, comparisons between Italian and immigrant CKD patients are still lacking, thus we aimed to describe the baseline clinical characteristics and the main outcomes of CKD patients who immigrated to Italy and reside in the Emilia Romagna region.
METHODS: This is a retrospective cohort study based on CKD patients from the Prevenzione Insufficienza Renale Progressiva (PIRP) project, which included 963 (3.1%) immigrants among the 30,702 patients seen by nephrologists between April 1st, 2004 and June 30th, 2020. We sub-divided the immigrants into seven groups based on their area of origin, and compared their baseline characteristics, CKD progression and time to end-stage kidney disease (ESKD) to those of Italian CKD patients.
RESULTS: At presentation, Italian subjects were on average older (73.1 years) and had less preserved kidney function (eGFR 34.3 ml/min), while South and East Asians had the highest proportion of diabetes and obesity (approximately 45% and 30%, respectively). At 4-year follow-up, about 20% of patients from South Asia, Eastern Europe and Arab Countries were diagnosed with ESKD, compared to only 11% of Italians and Latin Americans.
CONCLUSIONS: We found important differences between Italian and immigrant CKD patients, as well as among immigrant subgroups. First clinical encounters with nephrologists revealed that immigrants had varied patterns of clinical presentation and of nephropathy. During follow-up, immigrants showed faster kidney function decline which led to a higher risk of disease evolution and progression towards ESKD.
© 2021. Italian Society of Nephrology.

Entities:  

Keywords:  Access to healthcare; CKD prevention; Chronic kidney disease; Immigrant patients; PIRP

Mesh:

Year:  2021        PMID: 33595822     DOI: 10.1007/s40620-021-00984-5

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  8 in total

1.  Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.

Authors:  Yan Xie; Benjamin Bowe; Ali H Mokdad; Hong Xian; Yan Yan; Tingting Li; Geetha Maddukuri; Cheng-You Tsai; Tasheia Floyd; Ziyad Al-Aly
Journal:  Kidney Int       Date:  2018-08-03       Impact factor: 10.612

2.  The fermentation of L-sorbose by Gluconobacter melanogenus. II. Inducible formation of enzyme catalyzing conversion of L-sorbose to 2-keto-L-gulonic acid.

Authors:  Y Tsukada; D Perlman
Journal:  Biotechnol Bioeng       Date:  1972-09       Impact factor: 4.530

Review 3.  Psychosocial development in children with chronic renal insufficiency.

Authors:  W E Grupe; I Greifer; S I Greenspan; L A Leavitt; G Wolff
Journal:  Am J Kidney Dis       Date:  1986-04       Impact factor: 8.860

4.  Comparison of transbronchial and open lung biopsies in interstitial lung diseases.

Authors:  T Fortoul; M Selman; R Barrios; R Chapela
Journal:  Arch Invest Med (Mex)       Date:  1988 Jan-Mar

5.  Effect of oxamniquine on some biological features of schistosomiasis in white mice.

Authors:  N A Hammouda; A M El-Ridi; H O Abu Senna; N T Nasr; M F El-Sawi; M El-Sawi; M M Salama
Journal:  J Egypt Soc Parasitol       Date:  1983-06

6.  Retreat from Wenchebach.

Authors:  S Furman
Journal:  Pacing Clin Electrophysiol       Date:  1984-01       Impact factor: 1.976

7.  The role of salsolinol in alcohol intake and withdrawal.

Authors:  A Clow; A Topham; J B Saunders; R Murray; M Sandler
Journal:  Prog Clin Biol Res       Date:  1985

8.  [Comparison of 2 treatment schemes to eradicate Helicobacter pylori].

Authors:  P Hoffenberg; V Reyes; L Contreras; M Giglio; P Ossa; J C Weitz
Journal:  Rev Med Chil       Date:  1995-02       Impact factor: 0.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.